Logo image of MRT

MARTI TECHNOLOGIES INC (MRT) Stock Fundamental Analysis

NYSEARCA:MRT - NYSE Arca - US5731341039 - Common Stock - Currency: USD

3.451  -0.25 (-6.73%)

Fundamental Rating

2

Overall MRT gets a fundamental rating of 2 out of 10. We evaluated MRT against 39 industry peers in the Ground Transportation industry. MRT may be in some trouble as it scores bad on both profitability and health. MRT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRT has reported negative net income.
In the past year MRT has reported a negative cash flow from operations.
MRT Yearly Net Income VS EBIT VS OCF VS FCFMRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

MRT's Return On Assets of -84.09% is on the low side compared to the rest of the industry. MRT is outperformed by 94.74% of its industry peers.
Industry RankSector Rank
ROA -84.09%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRT Yearly ROA, ROE, ROICMRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -0.5 -1 -1.5

1.3 Margins

MRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRT Yearly Profit, Operating, Gross MarginsMRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

MRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRT Yearly Shares OutstandingMRT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M
MRT Yearly Total Debt VS Total AssetsMRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M

2.2 Solvency

MRT has an Altman-Z score of -2.24. This is a bad value and indicates that MRT is not financially healthy and even has some risk of bankruptcy.
MRT has a worse Altman-Z score (-2.24) than 86.84% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.24
ROIC/WACCN/A
WACC9.39%
MRT Yearly LT Debt VS Equity VS FCFMRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.47 indicates that MRT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.47, MRT belongs to the top of the industry, outperforming 81.58% of the companies in the same industry.
MRT has a Quick Ratio of 1.32. This is a normal value and indicates that MRT is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.32, MRT is doing good in the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.32
MRT Yearly Current Assets VS Current LiabilitesMRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MRT have decreased strongly by -1237.12% in the last year.
EPS 1Y (TTM)-1237.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-11.34%

3.2 Future

MRT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.38% yearly.
The Revenue is expected to grow by 22.56% on average over the next years. This is a very strong growth
EPS Next Y24.14%
EPS Next 2Y21.77%
EPS Next 3Y19.38%
EPS Next 5YN/A
Revenue Next Year-15.38%
Revenue Next 2Y-8.01%
Revenue Next 3Y22.56%
Revenue Next 5YN/A

3.3 Evolution

MRT Yearly Revenue VS EstimatesMRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
MRT Yearly EPS VS EstimatesMRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRT Price Earnings VS Forward Price EarningsMRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRT Per share dataMRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

MRT's earnings are expected to grow with 19.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.77%
EPS Next 3Y19.38%

More info and screens

0

5. Dividend

5.1 Amount

MRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARTI TECHNOLOGIES INC

NYSEARCA:MRT (2/21/2025, 8:04:02 PM)

3.451

-0.25 (-6.73%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)09-30 2024-09-30/bmo
Earnings (Next)N/A N/A
Inst Owners17.8%
Inst Owner Change236.57%
Ins Owners27.53%
Ins Owner Change0%
Market Cap197.95M
Analysts45
Price Target3.06 (-11.33%)
Short Float %0.27%
Short Ratio1.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.88
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.35
BVpS-0.57
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.16%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.32
Altman-Z -2.24
F-Score3
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1237.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.02%
EPS Next Y24.14%
EPS Next 2Y21.77%
EPS Next 3Y19.38%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-11.34%
Revenue Next Year-15.38%
Revenue Next 2Y-8.01%
Revenue Next 3Y22.56%
Revenue Next 5YN/A
EBIT growth 1Y-908.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.28%
EBIT Next 3Y31.84%
EBIT Next 5YN/A
FCF growth 1Y-201.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-799.52%
OCF growth 3YN/A
OCF growth 5YN/A